MRI Signs of Parkinson’s Disease and Atypical Parkinsonism

Abstract

Background Diagnosis of Parkinson’s disease and atypical parkinsonism is based on clinical evaluation of the patient’s symptoms and on magnetic resonance imaging (MRI) of the brain, which can be supplemented by nuclear medicine techniques. MRI plays a leading role in the differentiation between Parkinson’s disease and atypical parkinsonism. While atypical parkinsonism is characterized by relatively specific MRI signs, imaging of Parkinson’s disease previously lacked such signs. However, high-field MRI and new optimized MRI sequences now make it possible to define specific MRI signs of Parkinson’s disease and have significant potential regarding differentiated imaging, early diagnosis, and imaging of disease progression.

Methods PubMed was selectively searched for literature regarding the definition and discussion of specific MRI signs of Parkinson’s disease, as well as the most common types of atypical parkinsonism with a leading motor component. No time frame was set, but the search was particularly focused on current literature.

Results This review article discusses the different MRI signs of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. The pathogenesis of the MRI signs is described, and imaging examples are given. The technical aspects of image acquisition are briefly defined, and the different signs are discussed and compared with regard to their diagnostic significance according to current literature.

Conclusion The MRI signs of Parkinson’s disease, which can be defined with high-field MRI and new optimized MRI sequences, enable differentiated structural image interpretation and consecutive diagnostic workup. Despite the fact that the signs are in need of further validation by bigger studies, they have the potential to achieve significant diagnostic relevance regarding the imaging of Parkinson’s disease and atypical parkinsonism.

Key Points: 

• High-field MRI and specialized sequences make it possible to define specific MRI signs for neurodegenerative disorders

• Cerebral alterations can be detected in prodromal stages of Parkinson’s disease

• The combination of specific MRI signs makes it possible to differentiate between Parkinson’s disease and atypical parkinsonism

Citation Format

• Aludin S, Schmill LA. MRI Signs of Parkinson’s Disease and Atypical Parkinsonism. Fortschr Röntgenstr 2021; 193: 1403 – 1410

Key words

Parkinson’s disease - atypical parkinsonism - MR imaging

Publication History

Received: 30 October 2020

Accepted: 03 March 2021

Article published online:
25 May 2021

• References

• 1 de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. The Lancet Neurology 2006; 5: 525-535 DOI: 10.1016/S1474-4422(06)70471-9.
• 2 Reith W. Neurodegenerative Erkrankungen. Radiologe 2018; 58: 241-258 DOI: 10.1007/s00117-018-0363-y.
• 3 Kovacs GG. Molecular Pathological Classification of Neurodegenerative Diseases. Turning towards Precision Medicine. Int J Mol Sci 2016; 17 DOI: 10.3390/ijms17020189.
• 4 Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol 2018; 10: a033118 DOI: 10.1101/cshperspect.a033118.
• 5 Blazejewska AI, Schwarz ST, Pitiot A. et al Visualization of nigrosome 1 and its loss in PD. Pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013; 81: 534-540 DOI: 10.1212/WNL.0b013e31829e6fd2.
• 6 Sasaki M, Shibata E, Tohyama K. et al Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. Neuroreport 2006; 17: 1215-1218 DOI: 10.1097/01.wnr.0000227984.84927.a7.
• 7 Langkammer C, Pirpamer L, Seiler S. et al Quantitative Susceptibility Mapping in Parkinson’s Disease. PLoS ONE 2016; 11: e0162460 DOI: 10.1371/journal.pone.0162460.
• 8 Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord 2018; 46 (Suppl. 01) S30-S33 DOI: 10.1016/j.parkreldis.2017.07.033.
• 9 Ward RJ, Zucca FA, Duyn JH. et al The role of iron in brain ageing and neurodegenerative disorders. The Lancet Neurology 2014; 13: 1045-1060 DOI: 10.1016/S1474-4422(14)70117-6.
• 10 Damier P, Hirsch EC, Agid Y. et al The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999; 122: 1421-1436 DOI: 10.1093/brain/122.8.1421.
• 11 Lehéricy S, Bardinet E, Poupon C. et al 7 Tesla magnetic resonance imaging. A closer look at substantia nigra anatomy in Parkinson’s disease. Mov Disord 2014; 29: 1574-1581 DOI: 10.1002/mds.26043.
• 12 Schwarz ST, Afzal M, Morgan PS. et al The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinson’s Disease. A Case-Control and Retrospective Cross-Sectional MRI Study at 3T. PLoS ONE 2014; 9: e93814 DOI: 10.1371/journal.pone.0093814.
• 13 Schwarz ST, Mougin O, Xing Y. et al Parkinson’s disease related signal change in the nigrosomes 1–5 and the substantia nigra using T2* weighted 7T MRI. Neuroimage Clin 2018; 19: 683-689 DOI: 10.1016/j.nicl.2018.05.027.
• 14 Mahlknecht P, Krismer F, Poewe W. et al Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson’s disease. Mov Disord 2017; 32: 619-623 DOI: 10.1002/mds.26932.
• 15 Chau MT, Todd G, Wilcox R. et al Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson’s disease. A systematic review and meta-analysis. Parkinsonism Relat Disord 2020; 78: 12-20 DOI: 10.1016/j.parkreldis.2020.07.002.
• 16 Reiter E, Mueller C, Pinter B. et al Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord 2015; 30: 1068-1076 DOI: 10.1002/mds.26171.
• 17 Sugiyama A, Sato N, Kimura Y. et al MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism. Parkinsonism Relat Disord 2018; 48: 10-16 DOI: 10.1016/j.parkreldis.2017.12.021.
• 18 Kim JM, Jeong HJ, Bae YJ. et al Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 26: 47-54 DOI: 10.1016/j.parkreldis.2016.01.023.
• 19 Bae YJ, Kim JM, Kim KJ. et al Loss of Substantia Nigra Hyperintensity at 3.0-T MR Imaging in Idiopathic REM Sleep Behavior Disorder. Comparison with 123I-FP-CIT SPECT. Radiology 2018; 287: 285-293 DOI: 10.1148/radiol.2017162486.
• 20 Zucca FA, Basso E, Cupaioli FA. et al Neuromelanin of the human substantia nigra. An update. Neurotox Res 2014; 25: 13-23 DOI: 10.1007/s12640-013-9435-y.
• 21 Huddleston DE, Langley J, Dusek P. et al Imaging Parkinsonian Pathology in Substantia Nigra with MRI. Curr Radiol Rep 2018; 6: 154 DOI: 10.1007/s40134-018-0272-x.
• 22 Kim EY, Sung YH, Lee J. Nigrosome 1 imaging. Technical considerations and clinical applications. Br J Radiol 2019; 92: 20180842 DOI: 10.1259/bjr.20180842.
• 23 Xing Y, Sapuan A, Dineen RA. et al Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov Disord 2018; 33: 1792-1799 DOI: 10.1002/mds.27502.
• 24 Jin L, Wang J, Wang C. et al Combined Visualization of Nigrosome-1 and Neuromelanin in the Substantia Nigra Using 3T MRI for the Differential Diagnosis of Essential Tremor and de novo Parkinson’s Disease. Front Neurol 2019; 10: 100 DOI: 10.3389/fneur.2019.00100.
• 25 Trifonova OP, Maslov DL, Balashova EE. et al Parkinson’s Disease. Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization. Diagnostics (Basel) 2020; 10 DOI: 10.3390/diagnostics10050339.
• 26 Fabbri M, Reimão S, Carvalho M. et al Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson’s Disease. J Parkinsons Dis 2017; 7: 491-501 DOI: 10.3233/jpd-171135.
• 27 Sommerauer M, Fedorova TD, Hansen AK. et al Evaluation of the noradrenergic system in Parkinson’s disease. An 11C-MeNER PET and neuromelanin MRI study. Brain 2018; 141: 496-504 DOI: 10.1093/brain/awx348.
• 28 Pyatigorskaya N, Gaurav R, Arnaldi D. et al Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Sleep 2017; 40 DOI: 10.1093/sleep/zsx149.
• 29 Pyatigorskaya N, Gallea C, Garcia-Lorenzo D. et al A review of the use of magnetic resonance imaging in Parkinson’s disease. Ther Adv Neurol Disord 2014; 7: 206-220 DOI: 10.1177/1756285613511507.
• 30 Shinde S, Prasad S, Saboo Y. et al Predictive markers for Parkinson’s disease using deep neural nets on neuromelanin sensitive MRI. Neuroimage Clin 2019; 22: 101748 DOI: 10.1016/j.nicl.2019.101748.
• 31 Mochizuki H, Choong CJ, Baba K. Parkinson’s disease and iron. J Neural Transm (Vienna) 2020; 127: 181-187 DOI: 10.1007/s00702-020-02149-3.
• 32 Langkammer C, Schweser F, Krebs N. et al Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012; 62: 1593-1599 DOI: 10.1016/j.neuroimage.2012.05.049.
• 33 Martin-Bastida A, Lao-Kaim NP, Loane C. et al Motor associations of iron accumulation in deep grey matter nuclei in Parkinson’s disease. A cross-sectional study of iron-related magnetic resonance imaging susceptibility. Eur J Neurol 2017; 24: 357-365 DOI: 10.1111/ene.13208.
• 34 Zhao X, An H, Liu T. et al Quantitative Susceptibility Mapping of the Substantia Nigra in Parkinson’s Disease. Appl Magn Reson 2017; 48: 533-544 DOI: 10.1007/s00723-017-0877-x.
• 35 Chen Q, Chen Y, Zhang Y. et al Iron deposition in Parkinson’s disease by quantitative susceptibility mapping. BMC Neurosci 2019; 20: 23 DOI: 10.1186/s12868-019-0505-9.
• 36 Du G, Lewis MM, Sica C. et al Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson’s patients. Mov Disord 2018; 33: 1423-1431 DOI: 10.1002/mds.27318.
• 37 Ulla M, Bonny JM, Ouchchane L. et al Is R2* a new MRI biomarker for the progression of Parkinson’s disease? A longitudinal follow-up. PLoS ONE 2013; 8: e57904 DOI: 10.1371/journal.pone.0057904.
• 38 Lee JH, Lee MS. Brain Iron Accumulation in Atypical Parkinsonian Syndromes. In vivo MRI Evidences for Distinctive Patterns. Front Neurol 2019; 10: 74 DOI: 10.3389/fneur.2019.00074.
• 39 Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes. A systematic review and meta-analysis. Neurology 2013; 80: 857-864 DOI: 10.1212/wnl.0b013e318284070c.
• 40 Atkinson-Clement C, Pinto S, Eusebio A. et al Diffusion tensor imaging in Parkinson’s disease. Review and meta-analysis. Neuroimage Clin 2017; 16: 98-110 DOI: 10.1016/j.nicl.2017.07.011.
• 41 Andica C, Kamagata K, Hatano T. et al MR biomarkers of degenerative brain disorders derived from diffusion imaging. J Magn Reson Imaging 2019; DOI: 10.1002/jmri.27019.
• 42 Ofori E, Pasternak O, Planetta PJ. et al Increased free water in the substantia nigra of Parkinson’s disease. A single-site and multi-site study. Neurobiol Aging 2015; 36: 1097-1104 DOI: 10.1016/j.neurobiolaging.2014.10.029.
• 43 Zhang G, Zhang Y, Zhang C. et al Diffusion Kurtosis Imaging of Substantia Nigra Is a Sensitive Method for Early Diagnosis and Disease Evaluation in Parkinson’s Disease. Parkinsons Dis 2015; 2015: 207624 DOI: 10.1155/2015/207624.
• 44 Wang JJ, Lin WY, Lu CS. et al Parkinson disease. Diagnostic utility of diffusion kurtosis imaging. Radiology 2011; 261: 210-217 DOI: 10.1148/radiol.11102277.
• 45 Chougar L, Pyatigorskaya N, Degos B. et al The Role of Magnetic Resonance Imaging for the Diagnosis of Atypical Parkinsonism. Front Neurol 2020; 11: 665 DOI: 10.3389/fneur.2020.00665.
• 46 Saeed U, Compagnone J, Aviv RI. et al Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes. Current and emerging concepts. Transl Neurodegener 2017; 6: 8 DOI: 10.1186/s40035-017-0076-6.
• 47 Quattrone A, Nicoletti G, Messina D. et al MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246: 214-221 DOI: 10.1148/radiol.2453061703.
• 48 Barbagallo G, Sierra-Peña M, Nemmi F. et al Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord 2016; 31: 325-334 DOI: 10.1002/mds.26471.
• 49 Armstrong MJ. Progressive Supranuclear Palsy. An Update. Curr Neurol Neurosci Rep 2018; 18: 12 DOI: 10.1007/s11910-018-0819-5.
• 50 Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med 2011; 50: 1683-1687 DOI: 10.2169/internalmedicine.50.5101.
• 51 Mueller C, Hussl A, Krismer F. et al The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism Relat Disord 2018; 54: 90-94 DOI: 10.1016/j.parkreldis.2018.04.005.
• 52 Mangesius S, Hussl A, Krismer F. et al MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism Relat Disord 2018; 46: 47-55 DOI: 10.1016/j.parkreldis.2017.10.020.
• 53 Nigro S, Arabia G, Antonini A. et al Magnetic Resonance Parkinsonism Index. Diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. Eur Radiol 2017; 27: 2665-2675 DOI: 10.1007/s00330-016-4622-x.
• 54 Quattrone A, Morelli M, Williams DR. et al MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism. Neurology 2016; 87: 1266-1273 DOI: 10.1212/WNL.0000000000003125.